Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 7NIH 2OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Kaposi 1Immune Reconstitution Inflammatory Syndrome 1Acquired Immunodeficiency Syndrome 1

Interventions

Gemcitabine 15Cisplatin 12Radiotherapy 11Metformin 8Fluorouracil 8Capecitabine 8Paclitaxel 7Oxaliplatin 7Exercise 7Indocyanine Green 6Docetaxel 6Cyclophosphamide 6Control Groups 6Surveys and Questionnaires 5Standard of Care 5Nivolumab 5Letrozole 5Irinotecan 5pembrolizumab 4durvalumab 4Zoledronic Acid 4Vinorelbine 4Saline Solution 4Preoperative Exercise 4Magnetic Resonance Spectroscopy 4Leucovorin 4Ifosfamide 4Gefitinib 4Drug Therapy 4Carboplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × OTHER_GOV × Valganciclovir × Clear all
NCT03296553 2022-01-27

Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.

National Institute of Cancerología

Phase 2 Completed
40 enrolled 6 charts
Sarcoma

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi, Immune Reconstitution Inflammatory Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡